
Medicine or testing kit, prescribed online and delivered to your door.
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
If you only have a few minutes to spare, here’s what investors, operators, and founders should know about NURX (W16).
Nurx turned contraception and sexual-health care into a digital service: patients completed a health history online, received clinician review, and got medication or test kits delivered. Founded by Dr. Edvard Engesaeth and Hans Gangeskar and launched through Y Combinator in 2016, it later added migraine and dermatology care.[1][2]
This is not a failure story. Nurx proved that a politically sensitive, logistically awkward care category could support a durable consumer brand. Its 2022 merger with Thirty Madison shows the limit of the standalone model: clinical coverage, insurance, pharmacy operations, compliance, and patient acquisition become more economical when shared across conditions. Nurx survived as a brand because its wedge worked; the company consolidated because the infrastructure beneath that wedge rewarded scale.
Thirty Madison's merger announcement identifies Engesaeth and Gangeskar as the founders and says their aim was to remove barriers to essential care.[2] The company entered YC's Winter 2016 batch with a simple proposition: medicine and testing kits prescribed online and delivered to patients.[1] That framing mattered. Nurx did not begin as a general virtual clinic. It chose categories where privacy, convenience, recurring prescriptions, and uneven local access made an online front door unusually valuable.
The initial wedge was reproductive and sexual health, including contraception, STI testing, and HIV PrEP. Nurx later expanded into migraine and dermatology, with dermatology described as its fastest-growing service by the time of the merger.[2] The progression suggests a repeatable playbook: identify a condition with recurring treatment and access friction, then combine asynchronous intake, clinician review, fulfillment, and follow-up under one consumer brand.
The observed evidence does not establish the founders' detailed biographies, how they met, or the exact incident that produced the idea. It also contains no attributable full founder interview, so the canonical request for two verbatim founder quotations cannot be met honestly. The defensible founding story is narrower: two founders took a focused access problem through YC, proved the workflow in reproductive health, and broadened the operating model after the first wedge gained scale.
Nurx packaged several difficult tasks into one patient journey. A birth-control patient completes an online health-history consultation. A licensed provider reviews it, selects or approves treatment, and the service ships three months of medication. Automatic refills reduce interruption, while secure messaging gives the patient a route back to the medical team.[6]
The current service advertises more than 50 birth-control formulas, a $28 consultation, prices as low as $0 with insurance or $15 per month without it, discreet shipping, and controls to pause or cancel.[6] The product is therefore more than a video visit. Its value lies in coordinating intake, clinical decision-making, payment or insurance, fulfillment, refills, and longitudinal communication.
Read the complete post-mortem, the rebuild playbook, and the exact reasons NURX is still worth studying now.